Meaningful Use Stage 2 attestations remain lackluster

Laura Pedulli | | Health Exec | Policy & Regulations

 

Data released by the Centers for Medicare & Medicaid Services at the Health IT Policy Committee reveal only marginal gains in the numbers of eligible professionals and hospitals attesting to Meaningful Use (MU) Stage 2, reports Clinical Innovation + Technology.

As of November 2014, 11,478 eligible professionals and 840 hospitals have attested to MU Stage 2. “We’ve seen a significant increase in attestations over the past month,” Elisabeth Myers, head of policy and research at CMS’ Office of eHealth Standards and Services, told the committee, adding that she is expecting to see more attestations roll in thanks to the extended attestation reporting period. EPs have until Feb. 28, 2015, and EHs have until Dec. 31 to attest.

Read more below:

CMS reports rising Stage 2 attestations; CHIME says it’s not enough

Laura Pedulli

Related Content

Q&A: Proposed changes to Social Security Act would recognize pharmacists as healthcare providers
10 signs AI is ‘eating the world (of venture capital)’
Mangione now faces federal charges, death penalty in murder of UHC CEO
FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
DOJ sues CVS over unlawful opioid prescriptions and reimbursement

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.